Part Four - The impact of Erythropoietic Protoporphyria (EPP) on life

Mikey's quality of life, like all patients with Erythropoietic Protoporphyria (EPP), is severely affected. Severe pain forces him into living a nocturnal life or enduring outdoor activities in great discomfort or pain.

Isolation and unrelenting pain from sun exposure greatly impacts the quality of life of EPP patients. With no effective treatment currently available to them, sun avoidance is their only option. Forced to remain indoors, EPP patients eventually succumb to a nocturnal existence, the only way of life for many porphyria patients.

Throughout his life Mikey has been unable to experience the outdoor activities that many take for granted without the protection of clothing that completely blocks the sun such as a boiler suit, balaclava and gloves. Socialising with friends is difficult and "the pain just isn't worth it" so he avoids social situations where he will be outside.

Most people cannot understand how sensitive EPP patients are to sunlight and the intensity of pain they experience when exposed.

Clinuvel Blog Posts

The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...

Read More

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Clinuvel Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more